[Peptide vaccination for castration-resistant prostate cancer]

Area of Science:

• Oncology
• Immunology
• Vaccinology

Context:

• Prostate cancer exhibits significant heterogeneity in tumor cells and immune responses.
• Individual patient immune repertoires influence anti-tumor immunity.
• Existing immune status is a critical factor for vaccine efficacy.

Purpose:

• To introduce a personalized peptide vaccination (PPV) strategy for prostate cancer.
• To select optimal peptide vaccines based on HLA-A type and pre-existing immunity.
• To evaluate the clinical benefit of PPV in castration-resistant prostate cancer.

Summary:

• Developed a novel personalized peptide vaccination (PPV) approach.
• PPV selects up to four HLA-class I-matched peptides based on patient's HLA type and pre-existing immunity.
• Clinical studies in castration-resistant prostate cancer are discussed.

Impact:

• PPV offers a tailored immunotherapeutic strategy for prostate cancer.
• Potential to induce potent anti-tumor responses and clinical benefit.
• Advances the development of next-generation therapeutic cancer vaccines.